Bone Morphogenic Protein-4 Induces Hypertension in Mice
- 20 June 2006
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 113 (24), 2818-2825
- https://doi.org/10.1161/circulationaha.106.611822
Abstract
Background— Recent in vitro studies have shown that disturbed flow and oxidative conditions induce the expression of bone morphogenic proteins (BMPs 2 and 4) in cultured endothelial cells. BMPs can stimulate superoxide production and inflammatory responses in endothelial cells, raising the possibility that BMPs may play a role in vascular diseases such as hypertension and atherosclerosis. In this study, we examined the hypothesis that BMP4 would induce hypertension in intact animals by increasing superoxide production from vascular nicotinamide adenine dinucleotide phosphate (NADPH) oxidases and an impairment of vasodilation responses. Methods and Results— BMP4 infusion by osmotic pumps increased systolic blood pressure in a time- and dose-dependent manner in both C57BL/6 mice (from 101 to 125 mm Hg) and apolipoprotein E–null mice (from 107 to 146 mm Hg) after 4 weeks. Cotreatment with the BMP antagonist noggin or the NADPH oxidase inhibitor apocynin completely blocked the BMP4 effect. In addition, BMP4 infusion stimulated aortic NADPH oxidase activity and impaired vasorelaxation, both of which were prevented either by coinfusing noggin or by treating the isolated aortas with apocynin. BMP4, however, did not cause significant changes in maximum relaxation induced by the endothelium-independent vasodilator nitroglycerin. Remarkably, BMP4 infusion failed to stimulate aortic NADPH oxidases, increase blood pressure, and impair vasodilation responses in p47phox-deficient mice. Conclusions— These results suggest that BMP4 infusion induces hypertension in mice in a vascular NADPH oxidase–dependent manner and the subsequent endothelial dysfunction. We suggest that BMP4 is a novel mediator of endothelial dysfunction and hypertension and that noggin and its analogs could be used as therapeutic agents for treating vascular diseases.This publication has 37 references indexed in Scilit:
- Bone Morphogenetic Protein 4 Promotes Pulmonary Vascular Remodeling in Hypoxic Pulmonary HypertensionCirculation Research, 2005
- Angiotensin II-Dependent Chronic Hypertension and Cardiac Hypertrophy Are Unaffected by gp91phox-Containing NADPH OxidaseHypertension, 2005
- BMPR-IIheterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxiaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Functional association of nox1 with p22phox in vascular smooth muscle cellsFree Radical Biology & Medicine, 2004
- Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative BMPRII Gene in Smooth MuscleCirculation Research, 2004
- Mineral Exploration: Search for the Mechanism of Vascular Calcification and BeyondArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Bone Morphogenic Protein 4 Produced in Endothelial Cells by Oscillatory Shear Stress Stimulates an Inflammatory ResponsePublished by Elsevier BV ,2003
- Spin Trapping of Superoxide Radicals and Peroxynitrite by 1-Hydroxy-3-carboxy-pyrrolidine and 1-Hydroxy-2,2,6,6-tetramethyl-4-oxo-piperidine and the Stability of Corresponding Nitroxyl Radicals Towards Biological ReductantsBiochemical and Biophysical Research Communications, 1997
- The Reaction of no With SuperoxideFree Radical Research Communications, 1993
- Studies of the Effect of Glyceryl Trinitrate and Cyclic GMP on Calcium Turnover in Bovine Mesenteric ArteryBasic & Clinical Pharmacology & Toxicology, 1990